ArticleCureus2025
Placental Growth Factor as a Predictor of Adverse Maternal Outcomes in Patients With Hypertensive Disorders of Pregnancy: A Prospective Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond Diagnostic Cut-Offs: Associations Between the sFlt-1/PlGF Ratio and Perinatal Outcomes in Low-Risk Term Pregnancies.Journal of clinical medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHypertensive disorders of pregnancy (HDP) are among the leading causes of maternal and perinatal morbidity and mortality, primarily due to angiogenic imbalance and impaired vascular remodeling, resulting in elevated blood pressure and multiorgan involvement. Early detection of these conditions is crucial to improve outcomes. This study evaluates the role of serum placental growth factor (PLGF) as a biomarker for the severity of HDP and its association with maternal and neonatal outcomes. The objective of the study is to establish the diagnostic efficacy of serum PLGF in predicting adverse maternal outcomes in women diagnosed with HDP. MATERIALS AND
methodsA prospective observational study was conducted at the Department of Obstetrics and Gynaecology, B.L.D.E. (Deemed to be University), Shri B.M. Patil Medical College Hospital and Research Centre, Vijayapura. A total of 164 pregnant women diagnosed with HDP were enrolled after obtaining informed consent. Peripheral venous blood samples were collected on admission for serum PLGF testing using ELISA (enzyme-linked immunosorbent assay). Participants were monitored for maternal and perinatal outcomes (as per the American College of Obstetricians and Gynecologists (ACOG) guidelines), and correlations between PLGF levels and disease severity were analyzed.
resultsOf 164 hypertensive women, 91 (55.5%) had normal and 73 (45.5%) had low PLGF values. Significant associations (p < 0.05) were found between low PLGF and clinical/laboratory variables, including mode of delivery, imminent signs, hypertensive category, urine albumin, amniotic fluid volume, adverse maternal complications, and neonatal outcomes. A negative correlation was noted between PLGF and both systolic and diastolic blood pressures. The sensitivity and negative predictive values of PLGF were 83.5% and 72.1%, respectively.
conclusionSerum PLGF levels are significantly associated with the severity of HDP and with adverse maternal and perinatal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.